Peterson Amy C.
- SEC CIK
- 0001682735
No open-market purchases or sales filed in the past year.
Current role at each company
- EXEL Exelixis, Inc.EVP Prod Dev & Med Aff & CMOas of May 16, 2025
- CTMX CytomX Therapeutics, Inc.EVP, Chief Development Officeras of Mar 20, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Peterson Amy C. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
EXEL Exelixis, Inc.
EVP Prod Dev & Med Aff & CMO1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 16, 2025 (view filing) | May 16 | Same day | Peterson Amy C.EVP Prod Dev & Med Aff & CMO | SSale | −72.8K | $45.47 | −$3.31M | −13.5%465.4K after |
CTMX CytomX Therapeutics, Inc.
EVP, Chief Development Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 20, 2023 (view filing) | Mar 16 | 4 days | Peterson Amy C.EVP, Chief Development Officer | SSale | −4.26K | $1.98 | −$8.43K | −6.8%58.4K after | |
| Jul 21, 2022 (view filing) | Jul 20 | 1 day | Peterson Amy C.EVP, Chief Development Officer | SSale | −7.46K | $1.42 | −$10.6K | −10.6%62.7K after |